Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study.
Wu Z, Nickel B, Boroumand F, Elder D, Ferguson PM, Scolyer RA, O'Brien B, Barnhill R, Adamson AS, van Akkooi ACJ, Emery J, Parker L, Low D, Low C, Davies E, Liu S, Lewis S, Spongberg-Ross B, Bell KJ. Wu Z, et al. Among authors: van akkooi acj. BMJ Open. 2024 Dec 20;14(12):e089558. doi: 10.1136/bmjopen-2024-089558. BMJ Open. 2024. PMID: 39806624 Clinical Trial.
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea AM, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M; European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization for Research and Treatment of Cancer (EORTC). Garbe C, et al. Among authors: van akkooi acj. Eur J Cancer. 2025 Jan 17;215:115153. doi: 10.1016/j.ejca.2024.115153. Epub 2024 Nov 29. Eur J Cancer. 2025. PMID: 39709737 Free article.
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dréno B, Eggermont AMM, Fargnoli MC, Forsea AM, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M; European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization for Research and Treatment of Cancer (EORTC). Garbe C, et al. Among authors: van akkooi acj. Eur J Cancer. 2025 Jan 17;215:115152. doi: 10.1016/j.ejca.2024.115152. Epub 2024 Nov 28. Eur J Cancer. 2025. PMID: 39700658 Free article.
Clinical significance of intra-thoracic and intra-abdominal sentinel lymph nodes detected on lymphoscintigraphy in truncal melanoma patients.
Novis E, Sulaiman A, Stretch J, Chung D, London K, Wong T, Lo SN, Pennington TE, Saw RPM, Ch'ng S, Shannon KF, Spillane AJ, Nieweg OE, Thompson JF, van Akkooi ACJ, Rtshiladze M. Novis E, et al. Among authors: van akkooi acj. Eur J Surg Oncol. 2024 Dec 9;51(2):109538. doi: 10.1016/j.ejso.2024.109538. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 39662108
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.
Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, van Houdt WJ, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Eriksson H, Hospers GAP, Klop WMC, Torres Acosta A, Grijpink-Ongering L, Gonzalez M, van der Wal A, Al-Mamgani A, Spillane AJ, Scolyer RA, van de Wiel BA, van Akkooi ACJ, Long GV, Blank CU. Reijers ILM, et al. Among authors: van akkooi acj. Eur J Cancer. 2025 Jan;214:115141. doi: 10.1016/j.ejca.2024.115141. Epub 2024 Nov 19. Eur J Cancer. 2025. PMID: 39602990 Clinical Trial.
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.
Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L. Weber J, et al. Among authors: van akkooi acj. Oncologist. 2024 Nov 19:oyae289. doi: 10.1093/oncolo/oyae289. Online ahead of print. Oncologist. 2024. PMID: 39560953 Free article.
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Muñoz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Amaral T, et al. Among authors: van akkooi acj. Ann Oncol. 2025 Jan;36(1):10-30. doi: 10.1016/j.annonc.2024.11.006. Epub 2024 Nov 14. Ann Oncol. 2025. PMID: 39550033 No abstract available.
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases.
DePalo DK, Dugan MM, Naqvi SMH, Ollila DW, Hieken TJ, Block MS, van Houdt WJ, Wouters MWJM, Reijers SJM, Asher N, Broman KK, Duncan Z, Anderson M, Gyorki DE, Snow H, Held J, Farma JM, Vetto JT, Hui JYC, Kolbow M, Saw RPM, Lo SN, Long GV, Thompson JF, Kim Y, Karapetyan L, Ny L, van Akkooi ACJ, Olofsson Bagge R, Zager JS. DePalo DK, et al. Among authors: van akkooi acj. Cancer. 2025 Jan 1;131(1):e35636. doi: 10.1002/cncr.35636. Epub 2024 Nov 10. Cancer. 2025. PMID: 39522025
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Kreplere C, Marreaud S, Suciu S, Robert C. Eggermont AM, et al. Among authors: van akkooi acj. Eur J Cancer. 2024 Nov;211:114327. doi: 10.1016/j.ejca.2024.114327. Epub 2024 Sep 12. Eur J Cancer. 2024. PMID: 39288737 Clinical Trial.
Reply to: Pioneering combination: Nivolumab and isolated limb perfusion in melanoma in-transit metastases treatment.
Holmberg CJ, Zijlker LP, Katsarelias D, Huibers AE, Wouters MWJM, Schrage Y, Reijers SJM, van Thienen JV, Grünhagen DJ, Martner A, Nilsson JA, van Akkooi ACJ, Ny L, van Houdt WJ, Olofsson Bagge R. Holmberg CJ, et al. Among authors: van akkooi acj. Eur J Surg Oncol. 2024 Dec;50(12):108653. doi: 10.1016/j.ejso.2024.108653. Epub 2024 Sep 7. Eur J Surg Oncol. 2024. PMID: 39266404 No abstract available.
221 results